257 related articles for article (PubMed ID: 32554541)
1. Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE).
Talhouk A; George J; Wang C; Budden T; Tan TZ; Chiu DS; Kommoss S; Leong HS; Chen S; Intermaggio MP; Gilks B; Nazeran TM; Volchek M; Elatre W; Bentley RC; Senz J; Lum A; Chow V; Sudderuddin H; Mackenzie R; Leong SCY; Liu G; Johnson D; Chen B; Group A; Alsop J; Banerjee SN; Behrens S; Bodelon C; Brand AH; Brinton L; Carney ME; Chiew YE; Cushing-Haugen KL; Cybulski C; Ennis D; Fereday S; Fortner RT; García-Donas J; Gentry-Maharaj A; Glasspool R; Goranova T; Greene CS; Haluska P; Harris HR; Hendley J; Hernandez BY; Herpel E; Jimenez-Linan M; Karpinskyj C; Kaufmann SH; Keeney GL; Kennedy CJ; Köbel M; Koziak JM; Larson MC; Lester J; Lewsley LA; Lissowska J; Lubiński J; Luk H; Macintyre G; Mahner S; McNeish IA; Menkiszak J; Nevins N; Osorio A; Oszurek O; Palacios J; Hinsley S; Pearce CL; Pike MC; Piskorz AM; Ray-Coquard I; Rhenius V; Rodriguez-Antona C; Sharma R; Sherman ME; De Silva D; Singh N; Sinn P; Slamon D; Song H; Steed H; Stronach EA; Thompson PJ; Tołoczko A; Trabert B; Traficante N; Tseng CC; Widschwendter M; Wilkens LR; Winham SJ; Winterhoff B; Beeghly-Fadiel A; Benitez J; Berchuck A; Brenton JD; Brown R; Chang-Claude J; Chenevix-Trench G; deFazio A; Fasching PA; García MJ; Gayther SA; Goodman MT; Gronwald J; Henderson MJ; Karlan BY; Kelemen LE; Menon U; Orsulic S; Pharoah PDP; Wentzensen N; Wu AH; Schildkraut JM; Rossing MA; Konecny GE; Huntsman DG; Huang RY; Goode EL; Ramus SJ; Doherty JA; Bowtell DD; Anglesio MS
Clin Cancer Res; 2020 Oct; 26(20):5411-5423. PubMed ID: 32554541
[TBL] [Abstract][Full Text] [Related]
2. Pooled Clustering of High-Grade Serous Ovarian Cancer Gene Expression Leads to Novel Consensus Subtypes Associated with Survival and Surgical Outcomes.
Wang C; Armasu SM; Kalli KR; Maurer MJ; Heinzen EP; Keeney GL; Cliby WA; Oberg AL; Kaufmann SH; Goode EL
Clin Cancer Res; 2017 Aug; 23(15):4077-4085. PubMed ID: 28280090
[No Abstract] [Full Text] [Related]
3. Molecular subtyping of serous ovarian tumors reveals multiple connections to intrinsic breast cancer subtypes.
Jönsson JM; Johansson I; Dominguez-Valentin M; Kimbung S; Jönsson M; Bonde JH; Kannisto P; Måsbäck A; Malander S; Nilbert M; Hedenfalk I
PLoS One; 2014; 9(9):e107643. PubMed ID: 25226589
[TBL] [Abstract][Full Text] [Related]
4. Distinct transcriptional programs stratify ovarian cancer cell lines into the five major histological subtypes.
Barnes BM; Nelson L; Tighe A; Burghel GJ; Lin IH; Desai S; McGrail JC; Morgan RD; Taylor SS
Genome Med; 2021 Sep; 13(1):140. PubMed ID: 34470661
[TBL] [Abstract][Full Text] [Related]
5. Molecular subtypes of serous borderline ovarian tumor show distinct expression patterns of benign tumor and malignant tumor-associated signatures.
Curry EW; Stronach EA; Rama NR; Wang YY; Gabra H; El-Bahrawy MA
Mod Pathol; 2014 Mar; 27(3):433-42. PubMed ID: 23948749
[TBL] [Abstract][Full Text] [Related]
6. Outcome-Related Differences in Gene Expression Profiles of High-Grade Serous Ovarian Cancers Following Neoadjuvant Chemotherapy.
Octeau D; Kessous R; Klein K; Kogan L; Pelmus M; Ferenczy A; Greenwood CMT; Van Kempen LC; Salvador S; Lau S; Tonin PN; Yasmeen A; Gotlieb WH
Mol Cancer Res; 2019 Dec; 17(12):2422-2431. PubMed ID: 31530633
[TBL] [Abstract][Full Text] [Related]
7. A single-cell landscape of high-grade serous ovarian cancer.
Izar B; Tirosh I; Stover EH; Wakiro I; Cuoco MS; Alter I; Rodman C; Leeson R; Su MJ; Shah P; Iwanicki M; Walker SR; Kanodia A; Melms JC; Mei S; Lin JR; Porter CBM; Slyper M; Waldman J; Jerby-Arnon L; Ashenberg O; Brinker TJ; Mills C; Rogava M; Vigneau S; Sorger PK; Garraway LA; Konstantinopoulos PA; Liu JF; Matulonis U; Johnson BE; Rozenblatt-Rosen O; Rotem A; Regev A
Nat Med; 2020 Aug; 26(8):1271-1279. PubMed ID: 32572264
[TBL] [Abstract][Full Text] [Related]
8. Platform-Independent Classification System to Predict Molecular Subtypes of High-Grade Serous Ovarian Carcinoma.
Shilpi A; Kandpal M; Ji Y; Seagle BL; Shahabi S; Davuluri RV
JCO Clin Cancer Inform; 2019 Apr; 3():1-9. PubMed ID: 31002564
[TBL] [Abstract][Full Text] [Related]
9. Establishment of a Novel Histopathological Classification of High-Grade Serous Ovarian Carcinoma Correlated with Prognostically Distinct Gene Expression Subtypes.
Murakami R; Matsumura N; Mandai M; Yoshihara K; Tanabe H; Nakai H; Yamanoi K; Abiko K; Yoshioka Y; Hamanishi J; Yamaguchi K; Baba T; Koshiyama M; Enomoto T; Okamoto A; Murphy SK; Mori S; Mikami Y; Minamiguchi S; Konishi I
Am J Pathol; 2016 May; 186(5):1103-13. PubMed ID: 26993207
[TBL] [Abstract][Full Text] [Related]
10. Determination of BRAF V600E (VE1) protein expression and BRAF gene mutation status in codon 600 in borderline and low-grade ovarian cancers.
Sadlecki P; Walentowicz P; Bodnar M; Marszalek A; Grabiec M; Walentowicz-Sadlecka M
Tumour Biol; 2017 May; 39(5):1010428317706230. PubMed ID: 28488545
[TBL] [Abstract][Full Text] [Related]
11. Ovarian high-grade serous carcinoma with a noninvasive growth pattern simulating a serous borderline tumor.
Imamura H; Ohishi Y; Aman M; Shida K; Shinozaki T; Yasutake N; Sonoda K; Kato K; Oda Y
Hum Pathol; 2015 Oct; 46(10):1455-63. PubMed ID: 26232113
[TBL] [Abstract][Full Text] [Related]
12. Molecular classification of high grade endometrioid and clear cell ovarian cancer using TCGA gene expression signatures.
Winterhoff B; Hamidi H; Wang C; Kalli KR; Fridley BL; Dering J; Chen HW; Cliby WA; Wang HJ; Dowdy S; Gostout BS; Keeney GL; Goode EL; Konecny GE
Gynecol Oncol; 2016 Apr; 141(1):95-100. PubMed ID: 27016234
[TBL] [Abstract][Full Text] [Related]
13. High-grade serous tubo-ovarian cancer refined with single-cell RNA sequencing: specific cell subtypes influence survival and determine molecular subtype classification.
Olbrecht S; Busschaert P; Qian J; Vanderstichele A; Loverix L; Van Gorp T; Van Nieuwenhuysen E; Han S; Van den Broeck A; Coosemans A; Van Rompuy AS; Lambrechts D; Vergote I
Genome Med; 2021 Jul; 13(1):111. PubMed ID: 34238352
[TBL] [Abstract][Full Text] [Related]
14. A cell-of-origin epigenetic tracer reveals clinically distinct subtypes of high-grade serous ovarian cancer.
Lo Riso P; Villa CE; Gasparoni G; Vingiani A; Luongo R; Manfredi A; Jungmann A; Bertolotti A; Borgo F; Garbi A; Lupia M; Laise P; Das V; Pruneri G; Viale G; Colombo N; Manzo T; Nezi L; Cavallaro U; Cacchiarelli D; Walter J; Testa G
Genome Med; 2020 Oct; 12(1):94. PubMed ID: 33121525
[TBL] [Abstract][Full Text] [Related]
15. Nicotinamide N-methyltransferase overexpression may be associated with poor prognosis in ovarian cancer.
Harmankaya İ; Akar S; Uğraş S; Güler AH; Ezveci H; Aydoğdu M; Çelik Ç
J Obstet Gynaecol; 2021 Feb; 41(2):248-253. PubMed ID: 32285726
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathologic and Molecular Features of Paired Cases of Metachronous Ovarian Serous Borderline Tumor and Subsequent Serous Carcinoma.
Chui MH; Xing D; Zeppernick F; Wang ZQ; Hannibal CG; Frederiksen K; Kjaer SK; Cope L; Kurman RJ; Shih IM; Wang TL; Vang R
Am J Surg Pathol; 2019 Nov; 43(11):1462-1472. PubMed ID: 31343420
[TBL] [Abstract][Full Text] [Related]
17. Consensus on Molecular Subtypes of High-Grade Serous Ovarian Carcinoma.
Chen GM; Kannan L; Geistlinger L; Kofia V; Safikhani Z; Gendoo DMA; Parmigiani G; Birrer M; Haibe-Kains B; Waldron L
Clin Cancer Res; 2018 Oct; 24(20):5037-5047. PubMed ID: 30084834
[No Abstract] [Full Text] [Related]
18. High expression of ENPP1 in high-grade serous ovarian carcinoma predicts poor prognosis and as a molecular therapy target.
Wang H; Ye F; Zhou C; Cheng Q; Chen H
PLoS One; 2021; 16(2):e0245733. PubMed ID: 33635867
[TBL] [Abstract][Full Text] [Related]
19. Ovarian cancer and the evolution of subtype classifications using transcriptional profiling†.
Cook DP; Vanderhyden BC
Biol Reprod; 2019 Sep; 101(3):645-658. PubMed ID: 31187121
[TBL] [Abstract][Full Text] [Related]
20. BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer.
Grisham RN; Iyer G; Garg K; Delair D; Hyman DM; Zhou Q; Iasonos A; Berger MF; Dao F; Spriggs DR; Levine DA; Aghajanian C; Solit DB
Cancer; 2013 Feb; 119(3):548-554. PubMed ID: 22930283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
